Human immunodeficiency virus and liver disease: An update.
Human immunodeficiency virus and liver disease: An update.
复制标题
DOI：
10.1002/hep.28150
复制
发表时间：
2015-12
期刊：
影响因子：
--
通讯作者：
Thomas D
中科院分区：
文献类型：
--
作者：
Sherman KE;Rockstroh J;Thomas D
HIV infection affects approximately 1.2 million persons in the United States and 35 million worldwide. Progression to advanced liver disease remains a leading cause death among HIV-infected persons in the U.S. and elsewhere. Though mortality from HIV complications has been dramatically reduced wherever effective combination antiretroviral therapy is utilized, there has been little impact on liver related mortality. Causes of liver disease in the setting of HIV infection include viral hepatitis, NAFLD/NASH, drug-associated toxicities, and other metabolic/genetic disorders which interact in an environment modulated by persistent immune activation and altered cytokine display. Despite significant advances in treatment of HCV and suppression of HBV, treatment and management principles remain challenging. Limited resources, fragmented healthcare and high levels of injection drug use, alcohol use and depression remain relevant issues in the HIV-infected patient.
